Modulators Of Atp Binding Cassette Transporters

Abstract: The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators (I) or a pharmaceutically acceptable salt thereof, wherein: Ht is a 5-membered heteroaromatic ring containing 1-4 heteroatoms selected from O, S, N or NH, wherein said ring is optionally fused to a 6-membered monocyclic or 10-membered bicyclic carbocyclic or heterocyclic, aromatic or non-aromatic ring, wherein Ht is optionally substituted with w occurrences of -WR, wherein w is 0-5; ring A is 3-7 membered monocyclic ring having 0-3 heteroatoms selected from O, S, N, or NH, wherein ring A is optionally substituted with q occurrences of QR; ring B is optionally fused to 5-6 membered carbocyclic or heterocyclic, aromatic or non-aromatic ring .

Patent Information

Application #

Filing Date

24 August 2006

Publication Number

21/2007

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

VERTEX PHARMACEUTICALS

130,WAVERLY STREET CAMBRIDGE,MA 02139

Inventors

1. HADIDA,RUAH,SARAH,S

2356,TORREY PINES, #16,LA JOLLA,CA 92037,

2. GROOTENHUIS,PETER,D.J.

4801,RIDING RIDGE ROAD, SAN DIEGO,CA 92130

3. MILLER,MARK,T.

5075,LA JOLLA BOULEVARD, #9,SAN DIEGO,CA 92109

4. HAMILTON,MATTHEW

24 MOCKINGBIRD ROAD, HACKETTSTOWN,NJ 07840

Specification

The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators (I) or a pharmaceutically acceptable salt thereof, wherein: Ht is a 5-membered heteroaromatic ring containing 1-4 heteroatoms selected from O, S, N or NH, wherein said ring is optionally fused to a 6-membered monocyclic or 10-membered bicyclic carbocyclic or heterocyclic, aromatic or non-aromatic ring, wherein Ht is optionally substituted with w occurrences of -WR, wherein w is 0-5; ring A is 3-7 membered monocyclic ring having 0-3 heteroatoms selected from O, S, N, or NH, wherein ring A is optionally substituted with q occurrences of QR; ring B is optionally fused to 5-6 membered carbocyclic or heterocyclic, aromatic or non-aromatic ring .

Documents

Application Documents

#	Name	Date
1	abstract-02407-kolnp-2006.jpg	2011-10-07
2	02407-kolnp-2006 priority document.pdf	2011-10-07
3	02407-kolnp-2006 pct form.pdf	2011-10-07
4	02407-kolnp-2006 international search authority report.pdf	2011-10-07
5	02407-kolnp-2006 international publication.pdf	2011-10-07
6	02407-kolnp-2006 form-5.pdf	2011-10-07
7	02407-kolnp-2006 form-3.pdf	2011-10-07
8	02407-kolnp-2006 form-1.pdf	2011-10-07
9	02407-kolnp-2006 drawings.pdf	2011-10-07
11	02407-kolnp-2006 correspondence others.pdf	2011-10-07
12	02407-kolnp-2006 claims.pdf	2011-10-07
13	02407-kolnp-2006 assignment.pdf	2011-10-07
14	02407-kolnp-2006 abstract.pdf	2011-10-07
15	2407-KOLNP-2006-PETITION UNDER RULE 137.pdf	2011-10-17
16	2407-KOLNP-2006-OTHERS.pdf	2011-10-17
17	2407-KOLNP-2006-FORM 2.pdf	2011-10-17
18	2407-KOLNP-2006-FORM 13.pdf	2011-10-17
19	2407-KOLNP-2006-FORM 1-1.1.pdf	2011-10-17
20	2407-KOLNP-2006-EXAMINATION REPORT REPLY RECIEVED.pdf	2011-10-17
21	2407-KOLNP-2006-DESCRIPTION (COMPLETE)-1.1.pdf	2011-10-17
22	2407-KOLNP-2006-AMANDED CLAIMS.pdf	2011-10-17
23	2407-KOLNP-2006-ABSTRACT-1.1.pdf	2011-10-17
24	2407-KOLNP-2006-(12-07-2013)CORRESPONDENCE.pdf	2013-07-12
25	2407-KOLNP-2006-(05-02-2016)-HEARING SUBMISSION-(ADVANCE COPY).pdf	2016-02-05
26	2407-KOLNP-2006-(05-02-2016)-CORRESPONDENCE.pdf	2016-02-05
27	2407-KOLNP-2006_EXAMREPORT.pdf	2016-06-30